<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362373</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI0750</org_study_id>
    <nct_id>NCT02362373</nct_id>
  </id_info>
  <brief_title>Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users</brief_title>
  <acronym>WESAIL</acronym>
  <official_title>Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a prospective, seven-month pilot study to explore
      pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the
      levonorgestrel intrauterine system (LNG IUS) for contraception. The investigators will enroll
      twenty women with well-controlled epilepsy maintained on stable anti-epileptic drugs (AED)
      therapy seeking the LNG IUS for contraception. The primary outcomes are AED levels and
      seizures before and after LNG IUS placement. Secondary outcomes include LNG levels, evidence
      of ovulation three weeks after insertion (serum progesterone &gt;3ng/ml), bleeding and spotting,
      endometrial thickness, continuation, satisfaction and adverse events (removals, expulsions,
      side effects). The investigators will conduct a baseline month assessment, insertion visit,
      and follow-up visits at 21 days, three months and six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures This pilot study consists of five study visits. Once preliminary eligibility
      is determined through a telephone screening interview, the first visit is scheduled.

      Visit 1 Enrollment/Baseline

        -  Review Eligibility

        -  Informed Consent

        -  Collect Baseline Information

        -  Vital Signs

        -  Pregnancy Test

        -  Complete Physical Exam including Pelvic exam,

        -  Chlamydia testing, and a Pap test if needed as per ASCCP (American Society for
           Colposcopy and Cervical Pathology) guidelines

        -  Receive diary to record any bleeding or spotting

        -  Receive condoms, if needed, for use until IUS insertion

        -  Sign release for contact of primary neurologist or epileptologist

        -  Study MD to contact participant's neurologist to notify of trial participation, and
           verify type and dose of AEDs

      Visit 2 Insertion/4-6 Weeks from Baseline

        -  Vital Signs

        -  Pregnancy Test

        -  Phlebotomy for hormone and AED levels

        -  Transvaginal ultrasound

        -  IUS Insertion

        -  Review and collect completed diary

        -  Receive new diary

      Visit 3/ Follow up 3 Weeks post IUS Insertion

        -  Vital Signs

        -  Phlebotomy for hormone and AED levels

        -  Transvaginal Ultrasound

        -  Review and collect completed diary

        -  Receive new diary

      Visit 4/Follow up 3 Months post IUS Insertion

        -  Vital Signs

        -  Phlebotomy for hormone and AED levels

        -  Transvaginal ultrasound

        -  Review and collect completed diary

        -  Receive new diary

        -  Acceptability Questionnaire

      Visit 5/ Exit 6 Months post IUS insertion

        -  Vital Signs

        -  Phlebotomy for hormone and AED levels

        -  Transvaginal Ultrasound

        -  Review and collect final completed diary

        -  Acceptability Questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level</measure>
    <time_frame>from baseline to 6 months after LNG IUS insertion</time_frame>
    <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of lamotrigine after IUD insertion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level</measure>
    <time_frame>from baseline to 6 months after LNG IUS insertion</time_frame>
    <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of levetiracetam after IUD insertion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level</measure>
    <time_frame>from baseline to 6 months after LNG IUS insertion</time_frame>
    <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of oxcarbazepine after IUD insertion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Seizure Frequency</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Number of participants with increased, unchanged or decreased mean monthly seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Continuing With IUD</measure>
    <time_frame>6 months</time_frame>
    <description>Women continuing the IUD for contraception at 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Epilepsy</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>levonorgestrel IUS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel IUS</intervention_name>
    <description>placement of levonorgestrel intrauterine system</description>
    <arm_group_label>levonorgestrel IUS</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age18-45 years

          2. Regular menstrual cycle of length 21-35 days

          3. Willing to use IUS for contraception

          4. Willing to use non-hormonal contraception for one month before insertion

          5. Stable AED therapy for at least two months

          6. Well-controlled epilepsy (2 or fewer seizures, other than simple partial, per month)

          7. Working telephone

          8. English Speaking

        Exclusion Criteria:

          1. Current pregnancy or pregnancy in the previous two months

          2. Breastfeeding with amenorrhea

          3. Hepatic p450 enzyme inducing medications other than AEDs (griseofulvin, rifampin, St.
             John's Wort, bosentan)

          4. Depomedroxyprogesterone acetate within previous six months

          5. Congenital or acquired uterine anomaly, including myomas, that distort the uterine
             cavity

          6. Acute pelvic infection or a history pelvic infection without subsequent intrauterine
             pregnancy

          7. Postpartum endometritis or infected abortion in the last three months

          8. Genital bleeding of unknown etiology

          9. Untreated lower genital tract infection (cervical or vaginal)

         10. Acute liver disease or liver tumor, benign or malignant

         11. HIV infection or partner with HIV infection

         12. Increased susceptibility to pelvic infection

         13. A previously inserted intrauterine device (IUD) that has not been removed

         14. Hypersensitivity to any component of the LNG IUS

         15. Known or suspected carcinoma of the breast

         16. Current abnormal cervical cytology other than ASCUS or a history of abnormal cervical
             cytology other than ASCUS without appropriate follow-up demonstrating no evidence of
             disease

         17. History of genital tract malignancy

         18. Current use of anti-coagulants

         19. Current alcoholism or drug abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Anne Davis</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>contraception</keyword>
  <keyword>drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Women With Epilepsy Receiving the LNG IUS</title>
          <description>There was one group in this pilot study. All women received the LNG IUS.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levonorgestrel IUS</title>
          <description>all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
levonorgestrel IUS: placement of levonorgestrel intrauterine system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level</title>
        <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of lamotrigine after IUD insertion.</description>
        <time_frame>from baseline to 6 months after LNG IUS insertion</time_frame>
        <population>13 out of 20 participants received lamotrigine while on IUD.</population>
        <group_list>
          <group group_id="O1">
            <title>Women With Epilepsy Receiving the LNG IUS</title>
            <description>There was one group in this pilot study. All women received the LNG IUS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level</title>
          <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of lamotrigine after IUD insertion.</description>
          <population>13 out of 20 participants received lamotrigine while on IUD.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level</title>
        <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of levetiracetam after IUD insertion.</description>
        <time_frame>from baseline to 6 months after LNG IUS insertion</time_frame>
        <population>5 out of 20 participants received levetiracetam while on IUD.</population>
        <group_list>
          <group group_id="O1">
            <title>Women With Epilepsy Receiving the LNG IUS</title>
            <description>There was one group in this pilot study. All women received the LNG IUS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level</title>
          <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of levetiracetam after IUD insertion.</description>
          <population>5 out of 20 participants received levetiracetam while on IUD.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level</title>
        <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of oxcarbazepine after IUD insertion.</description>
        <time_frame>from baseline to 6 months after LNG IUS insertion</time_frame>
        <population>3 out of 20 participants received oxcarbazepine while on IUD.</population>
        <group_list>
          <group group_id="O1">
            <title>Women With Epilepsy Receiving the LNG IUS</title>
            <description>There was one group in this pilot study. All women received the LNG IUS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level</title>
          <description>The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of oxcarbazepine after IUD insertion.</description>
          <population>3 out of 20 participants received oxcarbazepine while on IUD.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seizure Frequency</title>
        <description>Number of participants with increased, unchanged or decreased mean monthly seizure frequency.</description>
        <time_frame>baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Women With Epilepsy Receiving the LNG IUS</title>
            <description>There was one group in this pilot study. All women received the LNG IUS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seizure Frequency</title>
          <description>Number of participants with increased, unchanged or decreased mean monthly seizure frequency.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seizure control unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure control decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure control improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Continuing With IUD</title>
        <description>Women continuing the IUD for contraception at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Women With Epilepsy Receiving the LNG IUS</title>
            <description>There was one group in this pilot study. All women received the LNG IUS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Continuing With IUD</title>
          <description>Women continuing the IUD for contraception at 6 months</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Women With Epilepsy Receiving the LNG IUS</title>
          <description>There was one group in this pilot study. All women received the LNG IUS.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hemmorhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>seasonal allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>strep throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hip injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>herniated disc</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>shoulder surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pinched nerve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>bladder spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <description>One participant had a cyst that ruptured; conservative management was successful and no surgery was required.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Uterine cramping</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>vaginal itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>bacterial vaginosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Davis, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-4951</phone>
      <email>ard4@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

